Published Paper Details:

The focus of the present study is to develop and characterize mouth dissolving tablet of Erlotinib hydrochloride. Erlotinib Hydrochloride, a strong antineoplastic drug utilized in the treatment of numerous cancers, presents significant formulation difficulties due to its poor water solubility and unpleasant taste. This research focuses on the development and characterization of a mouth dissolving tablet (MDT) formulation of Erlotinib Hydrochloride aimed at raising patient compliance and therapeutic efficacy. The formulation employs a ?-cyclodextrin inclusion complex established via the method of kneading to minimize the drug's unpleasantness and improve its solubility. The optimized complex, with a drug-to-?-cyclodextrin ratio of 1:2, was incorporated into MDTs using the direct compression technique. Comprehensive pre-compression evaluations, including measurements of bulk density, tapped density, Carr's index, Hausner's ratio, and angle of repose, were performed to ensure suitable powder flow. Post-compression parameters such as tablet weight variation, hardness, friability, disintegration time (goal <30 seconds), and in vitro dissolution (evaluated in phosphate buffer 7.4, pH 7.4) were subsequently examined. Characterization tests, including UV and FTIR analysis, confirmed the effective development of the inclusion complex without any chemical interaction between the drug and excipients.The optimized formulation exhibited rapid disintegration, satisfactory mechanical strength, and an enhanced dissolution profile compared to the pure drug, thereby demonstrating effective solubility improve and improved bioavailability. For mask the inedible taste of drug ?-cyclodextrin inclusion complex prepared and additionally added the polymer Kyron T-314 that act as a taste masking agent and also superdisintegrant. These findings suggest that the developed mouth dissolving tablet of Erlotinib Hydrochloride is a promising dosage form for cancer therapy, particularly for patients with swallowing difficulties. Future work will maybe involve scale-up studies and in vivo evaluation to further validate the clinical potential of this formulation